225 BINNEY STREET, CAMBRIDGE, MA
Completes Acquisition of Apellis Pharmaceuticals
Reports Strong First Quarter 2026 Results
Annual Report to Security Holders
Earnings Release
PROPOSED ACQUISITION OF APELLIS INVESTOR WEBCAST
Chief Legal Officer Departure - Susan H. Alexander to Leave Biogen
Material disclosure
Reports Strong Fourth Quarter and Full Year 2025 Results and Provides Full Year 2026 Financial Guidance
Q1
FY 2024
Q3
Q2
FY 2023
Tender Offer Statement by Third Party
Tender Offer Statement by Issuer
Prospectus Filed Pursuant to Rule 424(b)(2)
S-3ASR
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Amended Schedule 13D - Ownership Report
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Initial Statement of Beneficial Ownership
Schedule 13D - Ownership Report
Amended Tender Offer Statement by Third Party
Free Writing Prospectus
Definitive Revised Proxy Statement